- Home
- BBW vs MYGN Comparison
BBW vs MYGN Comparison
Compare BBW & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBW
- MYGN
- Stock Information
- Founded
- BBW 1997
- MYGN 1991
- Country
- BBW United States
- MYGN United States
- Employees
- BBW N/A
- MYGN N/A
- Industry
- BBW Recreational Games/Products/Toys
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BBW Consumer Discretionary
- MYGN Health Care
- Exchange
- BBW Nasdaq
- MYGN Nasdaq
- Market Cap
- BBW 672.6M
- MYGN 642.0M
- IPO Year
- BBW 2004
- MYGN 1995
- Fundamental
- Price
- BBW $71.61
- MYGN $7.40
- Analyst Decision
- BBW Strong Buy
- MYGN Hold
- Analyst Count
- BBW 5
- MYGN 13
- Target Price
- BBW $68.80
- MYGN $13.50
- AVG Volume (30 Days)
- BBW 454.2K
- MYGN 1.3M
- Earning Date
- BBW 08-28-2025
- MYGN 11-06-2025
- Dividend Yield
- BBW 1.22%
- MYGN N/A
- EPS Growth
- BBW 25.62
- MYGN N/A
- EPS
- BBW 4.47
- MYGN N/A
- Revenue
- BBW $522,518,000.00
- MYGN $832,900,000.00
- Revenue This Year
- BBW $10.77
- MYGN $0.17
- Revenue Next Year
- BBW $1.53
- MYGN $6.19
- P/E Ratio
- BBW $16.20
- MYGN N/A
- Revenue Growth
- BBW 8.10
- MYGN 3.83
- 52 Week Low
- BBW $30.49
- MYGN $3.76
- 52 Week High
- BBW $75.85
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- BBW 63.51
- MYGN 66.01
- Support Level
- BBW $71.14
- MYGN $7.13
- Resistance Level
- BBW $75.85
- MYGN $7.80
- Average True Range (ATR)
- BBW 4.14
- MYGN 0.44
- MACD
- BBW 0.72
- MYGN 0.04
- Stochastic Oscillator
- BBW 74.99
- MYGN 78.61
About BBW Build-A-Bear Workshop Inc.
Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.